Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study
NCT04252612 · H. Lee Moffitt Cancer Center and Research Institute · EARLY_PHASE1 · withdrawn · last registry update 2023-06-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Poor accrual” | – | Registry record, H. Lee Moffitt Cancer Center and Research Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CALCR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-06-11Results posted on the registry: University of Missouri-Columbia, Miacalcin Calcitonin Salmon Nasal Spray (NCT03812991)
- 2024-05-29Results posted on the registry: H. Lundbeck A/S, Eptinezumab + Erenumab (NCT05284019)
- 2024-05-29Also stopped (terminated): H. Lundbeck A/S, Eptinezumab + Erenumab (NCT05284019)
- 2024-04-02Results posted on the registry: University of Maryland, Baltimore, Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe + Placebo (NCT05162027)
- 2024-04-02Also stopped (terminated): University of Maryland, Baltimore, Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe + Placebo (NCT05162027)
- 2024-03-27Results posted on the registry: Xeris Pharmaceuticals, PRAM9 + Regular Insulin + Pramlintide (NCT04074317)
- 2024-03-22Results posted on the registry: University of Maryland, Baltimore, Erenumab-Aooe (NCT05142228)
- 2024-03-22Also stopped (terminated): University of Maryland, Baltimore, Erenumab-Aooe (NCT05142228)
- 2023-09-29Also stopped (terminated): Diamond Headache Clinic, Galcanezumab (NCT05492695)
- 2023-09-21Phase 3 first posted: McGill University Health Centre/Research Institute of the McGill University Health Centre, Pramlintide + Lyumjev (NCT06046417)
- 2023-08-22Phase 3 first posted: Click Therapeutics, Inc., a drug against CALCR (NCT06004388)
- 2023-07-21Phase 3 first posted: University of Oxford, a drug against CALCR (NCT05955612)
- 2022-11-30Phase 3 first posted: Kafrelsheikh University, Lacosamide 50 MG Oral Tablet + Ibuprofen 400 mg (NCT05632133)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision